Compare Manhattan Associates Inc (MANH) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs TransMedics Group Inc — how do they compare? Manhattan Associates Inc trades at $192.8 (market cap $11.38B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Manhattan Associates Inc is far larger — about 3.7× TransMedics Group Inc's market cap, and Manhattan Associates Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| MANH | TMDX | |
|---|---|---|
Market Cap | $11.38B | $3.10B |
Sector | Technology | Technology |
52-Week High | $220.19 | $150.42 |
52-Week Low | $120.88 | $61.99 |
Enterprise Value | $11.25B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MANH trades at $191.05, down 2.37% on the day, but maintains a bullish technical outlook with strong moving average signals and support near $192. The company reported robust Q2 2026 earnings, beating EPS estimates with $1.39 versus $1.32 expected, driven by 26% cloud revenue growth. However, a legal investigation into fiduciary duties by Rosen Law Firm presents a headwind. Analyst consensus remains strongly bullish with a $210.33 price target and 80% buy ratings.
The stock offers upside potential from consistent earnings beats and cloud momentum, but faces risks from the ongoing legal probe and elevated valuation multiples. Net income is projected to dip slightly in 2026, necessitating careful monitoring of execution against guidance. The current price sits just above key support, with resistance at $199.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
